BR112022019226A2 - Radioimunoconjugados direcionados a fgfr3 e usos dos mesmos - Google Patents
Radioimunoconjugados direcionados a fgfr3 e usos dos mesmosInfo
- Publication number
- BR112022019226A2 BR112022019226A2 BR112022019226A BR112022019226A BR112022019226A2 BR 112022019226 A2 BR112022019226 A2 BR 112022019226A2 BR 112022019226 A BR112022019226 A BR 112022019226A BR 112022019226 A BR112022019226 A BR 112022019226A BR 112022019226 A2 BR112022019226 A2 BR 112022019226A2
- Authority
- BR
- Brazil
- Prior art keywords
- radioimmunoconjugates
- fgfr3
- targeted
- pharmaceutical compositions
- linker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993622P | 2020-03-23 | 2020-03-23 | |
| PCT/US2021/023755 WO2021195131A1 (en) | 2020-03-23 | 2021-03-23 | Fgfr3-targeted radioimmunoconjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019226A2 true BR112022019226A2 (pt) | 2022-11-08 |
Family
ID=77892654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019226A BR112022019226A2 (pt) | 2020-03-23 | 2021-03-23 | Radioimunoconjugados direcionados a fgfr3 e usos dos mesmos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230201384A1 (https=) |
| EP (1) | EP4126074A4 (https=) |
| JP (1) | JP2023518818A (https=) |
| KR (1) | KR20220157464A (https=) |
| CN (1) | CN115315274A (https=) |
| AR (1) | AR121643A1 (https=) |
| AU (1) | AU2021244464A1 (https=) |
| BR (1) | BR112022019226A2 (https=) |
| CA (1) | CA3176617A1 (https=) |
| CL (1) | CL2022002557A1 (https=) |
| IL (1) | IL295999A (https=) |
| MX (1) | MX2022011635A (https=) |
| TW (1) | TW202144008A (https=) |
| WO (1) | WO2021195131A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20240254A (es) * | 2021-12-20 | 2025-01-13 | Astrazeneca Uk Ltd | Compuestos dirigidos a egfr-cmet y usos de estos |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140030259A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| CA2961439A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| BR112017017700A2 (pt) * | 2015-02-19 | 2018-07-31 | Bioclin Therapeutics Inc | métodos, composições e kits para tratamento do câncer |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| WO2018204872A2 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| MA48861A (fr) * | 2017-05-05 | 2020-04-01 | Fusion Pharmaceuticals Inc | Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations |
| CN111868260B (zh) * | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| AU2021206233A1 (en) * | 2020-01-10 | 2022-08-11 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
-
2021
- 2021-03-23 KR KR1020227036615A patent/KR20220157464A/ko active Pending
- 2021-03-23 EP EP21775240.1A patent/EP4126074A4/en not_active Withdrawn
- 2021-03-23 AU AU2021244464A patent/AU2021244464A1/en not_active Abandoned
- 2021-03-23 JP JP2022557117A patent/JP2023518818A/ja active Pending
- 2021-03-23 CA CA3176617A patent/CA3176617A1/en active Pending
- 2021-03-23 TW TW110110479A patent/TW202144008A/zh unknown
- 2021-03-23 MX MX2022011635A patent/MX2022011635A/es unknown
- 2021-03-23 US US17/906,857 patent/US20230201384A1/en active Pending
- 2021-03-23 WO PCT/US2021/023755 patent/WO2021195131A1/en not_active Ceased
- 2021-03-23 IL IL295999A patent/IL295999A/en unknown
- 2021-03-23 BR BR112022019226A patent/BR112022019226A2/pt unknown
- 2021-03-23 AR ARP210100720A patent/AR121643A1/es not_active Application Discontinuation
- 2021-03-23 CN CN202180023427.1A patent/CN115315274A/zh active Pending
-
2022
- 2022-09-21 CL CL2022002557A patent/CL2022002557A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022002557A1 (es) | 2023-05-19 |
| KR20220157464A (ko) | 2022-11-29 |
| IL295999A (en) | 2022-10-01 |
| MX2022011635A (es) | 2022-10-13 |
| CA3176617A1 (en) | 2021-09-30 |
| AU2021244464A1 (en) | 2022-11-24 |
| EP4126074A1 (en) | 2023-02-08 |
| EP4126074A4 (en) | 2024-11-20 |
| AR121643A1 (es) | 2022-06-22 |
| CN115315274A (zh) | 2022-11-08 |
| JP2023518818A (ja) | 2023-05-08 |
| US20230201384A1 (en) | 2023-06-29 |
| WO2021195131A1 (en) | 2021-09-30 |
| TW202144008A (zh) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006841A (es) | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?. | |
| BR112023002417A2 (pt) | Conjugado de anticorpo e fármaco | |
| BR112021008903A2 (pt) | Compostos de piridazinona e usos dos mesmos | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112023021068A2 (pt) | Compostos, composições e métodos para tratar câncer | |
| MX2025013504A (es) | Inhibidores de kras de anillo fundido para el tratamiento de enfermedades | |
| BR112022019532A2 (pt) | Conjugados de neodegrader | |
| BR112023016614A2 (pt) | Inibidores de tyk2 e usos dos mesmos | |
| BR112022006001A2 (pt) | Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado | |
| BR112022007719A2 (pt) | Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| BR112019023246A8 (pt) | melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos | |
| PH12019502594A1 (en) | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| MX2022012471A (es) | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. | |
| MX2023014831A (es) | Conjugados inhibidores de la via de recuperacion de dinucleotido de nicotinamida adenina cuaternizados. | |
| BR112023022297A2 (pt) | Receptores quiméricos que alvejam adgre2 e/ou clec12a e usos dos mesmos | |
| BR112022024691A2 (pt) | Conjugados anticorpo biespecífico - fármaco direcionados a egfr e muc1 e usos dos mesmos | |
| MX2021007738A (es) | Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer. | |
| CR20240254A (es) | Compuestos dirigidos a egfr-cmet y usos de estos | |
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| BR112022013678A2 (pt) | Quelatos macrocíclicos e seus usos | |
| ZA202408803B (en) | Adenosine derivative and pharmaceutical composition comprising the same | |
| BR112023011315A2 (pt) | Imunoconjugado, composto, composição farmacêutica, método para tratamento de câncer e para preparar um imunoconjugado e uso de um imunoconjugado | |
| MX2023012204A (es) | Derivados de piperidina urea como inhibidores de la epóxido hidrolasa soluble. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |